Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b
Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
4 months since company announcement on 2 September 2024.
IMO, Management would be finalizing an abstract submission within the next few weeks for the AACR meeting from April 25 to 30, 2025.
Expecting an Azer-cel update before the abstract being accepted.
Regards.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |